News on muscle relaxants
The big news in the field of neuromuscular blocking agents is ... that there are no new drugs on the horizon. The shortage of money in the field of neuromuscular research derives from the simple fact that the pharmaceutical companies have no money to invest in market niches and perhaps from the perceived evidence that the drugs we have today are already highly sophisticated and there is no absolute need to improve them. Organon tried to launch a new fast-onset/fast-offset drug (rapacuronium), but it had dangerous side effects on the airways, especially a worrying incidence of bronchospasm and oxygen desaturations , and was therefore withdrawn from the formularies after a promising start. We are still short of a drug with clinical time actions similar to those of succinylcholine, and this is still a goal of pharmaceutical research in the field of the neuromuscular blocking agents, pushed by the continuous growth of day surgery/day anaesthesia.
KeywordsNeuromuscular Blockade Neuromuscular Block Neuromuscular Blocking Agent Reversal Agent Adductor Pollicis
Unable to display preview. Download preview PDF.
- 5.Camu G, de Baerdemaeker L, den Blauwen N et al (2002) Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol 19: 129–134Google Scholar
- 10.Berg H, Viby-Mogensen J, Roed J et al (1997) Residual neuromuscular block is a risk factor for postoperative pulmonary complications: a prospective, randomised and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 41: 1095–1103PubMedCrossRefGoogle Scholar
- 13.Lysakowski C, Fuchs-Buder T, Tassonyi E (2000) Mivacurium or vecuronium for paediatric ENT surgery. Clinical experience and cost analysis. Anaesthesist 49: 387–391Google Scholar